Congratulations To GenFleet Therapeutics For Selective CDK9 Inhibitor GFH009 Injection Approved For Clinical Trial by NMPA
Shanghai, December 21,2020 – Congratulations to GenFleet Therapeutics Inc. for their selective CDK9 inhibitor GFH009 Injection have been approved by the CDE (Center for Drug Evaluation), NMPA for clinical trials. It has received
December 21, 2020